Back to top
more

Myomo (MYO)

(Real Time Quote from BATS)

$4.50 USD

4.50
49,503

-0.20 (-4.26%)

Updated Jul 30, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod

by Zacks Equity Research

Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.

Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.

Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block

by Zacks Equity Research

Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.

Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GNC Holdings Inks Retail Partnership Deal to Grow in Brazil

by Zacks Equity Research

We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.

Innovation Aids Genomic Health, Merger Procedure on Track

by Zacks Equity Research

Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.

Insulet (PODD) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Insulet (PODD) has various favorable factors to maintain the current high.

Will Myomo, Inc. (MYO) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myomo, Inc. (MYO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -5.00% and -25.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Q3 Earnings Preview: What to Look Out For

by Zacks Equity Research

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -10.53% and 1.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?